New antibody combo aims to supercharge immune system against Hard-to-Treat cancers

NCT ID NCT04198766

Recruiting now Disease control Sponsor: Inhibrx Biosciences, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the combination can shrink tumors. About 296 adults are taking part across multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INBRX-106 (an experimental antibody that targets OX40 receptors on immune cells) and pembrolizumab (Keytruda, an immunotherapy drug)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early Phase 1/2 trial, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma epithelial neoplasm gastric cancer gastric neoplasm head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma hypopharynx cancer lung neoplasm melanoma Mouth Neoplasms nasopharyngeal carcinoma neoplasm Neoplasms by Histologic Type Neoplasms by Site non-small cell lung carcinoma oropharynx cancer renal cell carcinoma squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck squamous cell neoplasm transitional cell carcinoma urothelial carcinoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER HEAD AND NECK CANCER MELANOMA NON-SMALL CELL LUNG CANCER RENAL CELL CARCINOMA RESECTABLE NON-SMALL CELL LUNG CANCER SOLID TUMOR UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Asan Medical Center
ACTIVE_NOT_RECRUITING

Seoul, South Korea
Barbara Ann Karmanos Cancer Institute
COMPLETED

Detroit, Michigan, 48201, United States
California Research Institute
RECRUITING

Los Angeles, California, 90027, United States
Changhua Christian Hospital (CCH)
ACTIVE_NOT_RECRUITING

Changhua, Taiwan
City of Hope
RECRUITING

Duarte, California, 91010, United States
Clermont Oncology Center
RECRUITING

Clermont, Florida, 34711, United States
Cleveland Clinic
ACTIVE_NOT_RECRUITING

Cleveland, Ohio, 44195, United States
Curie Oncology
COMPLETED

Singapore, Singapore
E-Da Cancer Hospital
ACTIVE_NOT_RECRUITING

Kaohsiung City, Taiwan
Froedtert Hospital and the Medical College of Wisconsin
ACTIVE_NOT_RECRUITING

Milwaukee, Wisconsin, 53226, United States
HealthPartners Cancer Research Center
ACTIVE_NOT_RECRUITING

Saint Louis Park, Minnesota, 55426, United States
HealthPartners Cancer Research Center (Regions Hospital)
COMPLETED

Saint Paul, Minnesota, 55101, United States
Henry Ford Cancer Institute
RECRUITING

Detroit, Michigan, 48202, United States
Icon Cancer Centre Farrer Park
COMPLETED

Singapore, Singapore
Icon Cancer Centre Mount Alvernia
COMPLETED

Singapore, Singapore
Intermountain Health Cancer Centers of Montana
COMPLETED

Billings, Montana, 59102, United States
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
ACTIVE_NOT_RECRUITING

Kaohsiung City, Taiwan
Los Angeles Cancer Network
RECRUITING

Glendale, California, 91204, United States
Mid Florida Hematology and Oncology Center
RECRUITING

Orange City, Florida, 32763, United States
Montefiore Medical Center
ACTIVE_NOT_RECRUITING

The Bronx, New York, 10467, United States
NEXT Oncology
COMPLETED

San Antonio, Texas, 78229, United States
National Cheng Kung University Hospital
ACTIVE_NOT_RECRUITING

Tainan, Taiwan
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40202, United States
Providence Medical Foundation
RECRUITING

Santa Rosa, California, 95403, United States
Providence Portland Medical Center
ACTIVE_NOT_RECRUITING

Portland, Oregon, 97213, United States
Renovatio Clinical
COMPLETED

The Woodlands, Texas, 77380, United States
Renovatio Clinical - El Paso
COMPLETED

El Paso, Texas, 79915, United States
START Midwest
ACTIVE_NOT_RECRUITING

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute at Mary Crowley
COMPLETED

Dallas, Texas, 75230, United States
Severance Hospital, Yonsei University Health System
ACTIVE_NOT_RECRUITING

Seoul, South Korea
Taipei Veterans General Hospital
COMPLETED

Taipei, Taiwan
The Catholic University of Korea Seoul St. Mary's Hospital,
ACTIVE_NOT_RECRUITING

Seoul, South Korea
The Catholic University of Korea, St. Vincent's Hospital
ACTIVE_NOT_RECRUITING

Gyeonggi-do, South Korea
The University of Chicago Medical Center
ACTIVE_NOT_RECRUITING

Chicago, Illinois, 60637, United States
The University of Texas Health Science Center at Tyler
RECRUITING

Tyler, Texas, 75701, United States
University of Iowa
ACTIVE_NOT_RECRUITING

Iowa City, Iowa, 52242, United States
Valkyrie Clinical Trials
RECRUITING

Los Angeles, California, 90069, United States
Valkyrie Clinical Trials
RECRUITING

Murrieta, California, 92562, United States
Vanderbilt University School of Medicine
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37204, United States
Virginia Cancer Specialists
COMPLETED

Fairfax, Virginia, 22031, United States
Winship Cancer Institute - Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.